NVAX - מכפיל EV/EBITDA Novavax

Risks of declining demand for COVID-19 products are neutralized by partnerships, while the focus has shifted to the influenza vaccine. The EV/EBITDA business valuation level on GURU.Markets reflects the company's value dynamics, where the value 0.00 represents the current figure. Novavax, Inc. (NVAX) maintains stability through its Matrix-M biodefense platform and optimized international logistics, which minimize regulatory barriers during deliveries.

Novavax, Inc. (NVAX) specializes in developing protein-based vaccines for public healthcare systems, which requires significant capital expenditures. The multiple compares the total enterprise value to earnings before interest, taxes, depreciation, and amortization, allowing for an assessment of debt management efficiency; meanwhile, the company's trend EV/EBITDA level helps investors determine the risk of overpayment or the likelihood of an asset value correction.